We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Spectroscopy Aids Drug-Delivery Research

By Biotechdaily staff writers
Posted on 29 Mar 2005
Researchers are investigating transdermal drug delivery by using a new spectroscopy instrument that provides spatial distribution of various substances, allows skin-penetration pathways to be studied, and can measure protein as well as mineral content of bones.

The instrument, called Spectrum Spotlight 300 FT-IR (Fourier transform-infrared), is able to map the spatial distribution of penetration enhancers, pharmaceutical candidates, and other substances in various layers of the skin. More...
This is important in cases where the best therapeutic intervention requires delivery at particular concentrations to well-defined locations within the skin.

The Spectrum Spotlight FT-IR offers an array of detectors that acquire spatially resolved spectra very quickly in order to generate an infrared image of the sample, providing IR images in minutes rather than hours or days as was previously necessary. The instrument is the product of PerkinElmer Life and Analytical Sciences (Shelton, CT, USA).

The researchers, from Rutgers University (Newark, NJ, USA), have focused on liposomes for topical, dermal delivery of biologically active molecules. They have successfully used these for the delivery of low- and high-molecular weight molecules into the skin. As an alternative to a virus-mediated delivery system, they have opened the field of dermal gene delivery.

"An advantage of the imaging IR approach is that in addition to mapping of external substances introduced to the skin, the spatial relationships between these external substances and internal skin components may be monitored and correlated,” observed Richard Mendelsohn, professor of chemistry at Rutgers.





Related Links:
Rutgers
PerkinElmer

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.